0001729149-21-000068.txt : 20210503 0001729149-21-000068.hdr.sgml : 20210503 20210503172630 ACCESSION NUMBER: 0001729149-21-000068 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210503 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210503 DATE AS OF CHANGE: 20210503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIEMED HEALTHCARE, INC. CENTRAL INDEX KEY: 0001729149 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38973 FILM NUMBER: 21884812 BUSINESS ADDRESS: STREET 1: 625 E. KALISTE SALOOM RD. CITY: LAFAYETTE STATE: LA ZIP: 70508 BUSINESS PHONE: 337.504.3802 MAIL ADDRESS: STREET 1: 625 E. KALISTE SALOOM RD. CITY: LAFAYETTE STATE: LA ZIP: 70508 8-K 1 vmd-20210503.htm 8-K vmd-20210503
0001729149false00017291492021-05-032021-05-03

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2021
 
Viemed Healthcare, Inc.
(Exact name of registrant as specified in its charter)
  
British Columbia, Canada
001-38973N/A
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
625 E. Kaliste Saloom Rd.
Lafayette, Louisiana
70508
(Address of principal executive offices)(Zip Code)
(337) 504-3802
(Registrant’s telephone number, including area code) 


(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common shares, no par value
VMD
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02.     Results of Operations and Financial Condition.

On May 3, 2021, Viemed Healthcare, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2021. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the foregoing information, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and Exhibit 99.1 be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.    Financial Statements and Exhibits
(d)Exhibits
 
Exhibit
Number
Description
104     Cover Page Interactive Data File, formatted in Inline XBRL and included as Exhibit 101



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 3, 2021
 
VIEMED HEALTHCARE, INC.
By:
/s/ Trae Fitzgerald
Trae Fitzgerald
Chief Financial Officer
































EX-99.1 2 q12021earningsrelease.htm EX-99.1 Document

VIEMED HEALTHCARE ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS

Lafayette, Louisiana (May 3, 2021) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that it has reported its financial results for the three months ended March 31, 2021.

Operational highlights (all dollar amounts are USD):

Net revenues attributable to the Company's core business for the quarter ended March 31, 2021 were $25.5 million, an increase of $2.7 million or 12% over net core revenues reported for the comparable quarter ended March 31, 2020. Total net revenues for the current quarter were $28.4 million which included approximately $2.9 million for contact tracing services and product sales related to the COVID-19 pandemic.

Net income for the quarter ended March 31, 2021 totaled approximately $1.7 million, compared to $4.2 million for the quarter ended March 31, 2020. The 2020 quarter included $1.0 million of revenue and $2.5 million of proceeds on used equipment sales related to COVID-19 response sales and services.

Adjusted EBITDA for the quarter ended March 31, 2021 totaled approximately $5.5 million, a 31% decrease as compared to the quarter ended March 31, 2020. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.

The Company had a cash balance of $31.1 million at March 31, 2021 ($31.0 million at December 31, 2020) and an overall working capital balance of $26.4 million ($24.2 million at December 31, 2020). Total long-term debt as of March 31, 2021 was $6.1 million ($6.6 million at December 31, 2020).

The Company expects to generate net revenues attributable to its core business of approximately $26.2 million to $27.2 million during the second quarter of 2021. While the Company's COVID-19 response related business has slowed during the current year, the Company is continuing to pursue additional sales and support revenues and estimates second quarter 2021 revenues of approximately $0.5 million to $1.0 million related to the COVID-19 pandemic. Total revenues for the second quarter of 2021 are estimated to be approximately $26.7 million to $28.2 million.

“The first quarter will very likely be the quarter where things began to reopen from the COVID-19 pandemic and I am once again proud of our ability to keep servicing high need patients,” said Casey Hoyt, Viemed's CEO. “Our new patient uploads during March were the highest single month since the pandemic began and gave us the ability to grow our core business even with the challenges faced during January and February. We are excited to continue utilizing our new programs along with our traditional sales methods as more healthcare systems open around the country.”

Conference Call Details

The Company will host a conference call to discuss third quarter results on Tuesday, May 4, 2021 at 11:00 a.m. EST.

The call-in numbers for participants are:

US Toll Free Dial In: 1-877-407-0784
International Toll Free Dial In: 1-201-689-8560
Meeting ID Number: 13719010
Live Event Call me™ Link (Available 15 minutes prior to start time for participant entry)
https://callme.viavid.com/?callme=true&passcode=13707099&h=true&info=company-email&r=true&B=6

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com.




For further information, please contact:

Glen Akselrod
Bristol Capital
905-326-1888
glen@bristolir.com

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
investorinfo@viemed.com

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, or “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the second quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company’s novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.




VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of U.S. Dollars, except share amounts)
(Unaudited)
At
March 31, 2021
At
December 31, 2020
ASSETS
Current assets
Cash and cash equivalents$31,097 $30,981 
Accounts receivable, net of allowance for doubtful accounts of $7,999 and $9,013 at March 31, 2021 and December 31, 2020, respectively13,282 12,373 
Inventory, net of inventory reserve of $1,349 and $1,353 at March 31, 2021 and December 31, 2020, respectively2,220 2,310 
Prepaid expenses and other assets1,674 1,511 
Total current assets$48,273 $47,175 
Long-term assets
Property and equipment, net53,996 55,056 
Equity investments953 733 
Deferred tax asset8,918 8,733 
Other long-term assets861 863 
Total long-term assets$64,728 $65,385 
TOTAL ASSETS$113,001 $112,560 
LIABILITIES
Current liabilities
Trade payables$2,534 $2,096 
Deferred revenue3,422 3,409 
Income taxes payable340 340 
Accrued liabilities12,013 12,595 
Current portion of lease liabilities1,688 2,741 
Current portion of long-term debt1,858 1,836 
Total current liabilities$21,855 $23,017 
Long-term liabilities
Accrued liabilities1,654 1,292 
Long-term lease liabilities748 762 
Long-term debt5,323 5,796 
Total long-term liabilities$7,725 $7,850 
TOTAL LIABILITIES$29,580 $30,867 
Commitments and Contingencies— — 
SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 39,577,288 and 39,185,182 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively13,649 9,181 
Additional paid-in capital4,224 7,320 
Accumulated other comprehensive loss(345)(451)
Retained earnings65,893 65,643 
TOTAL SHAREHOLDERS' EQUITY$83,421 $81,693 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$113,001 $112,560 



VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)
(Unaudited)
Three Months Ended March 31,
20212020
Revenue$28,416 $23,806 
Cost of revenue10,674 8,253 
Gross profit$17,742 $15,553 
Operating expenses
Selling, general and administrative14,509 10,577 
Research and development339174 
Stock-based compensation1,307 1,151 
Depreciation200 205 
Loss (gain) on disposal of property and equipment76 (1,169)
     Other income(21)— 
Income from operations$1,332 $4,615 
Non-operating expenses
Loss (gain) from equity method investments(220)27
Interest expense, net of interest income91 158 
Net income before taxes1,461 4,430 
Provision (benefit) for income taxes(223)187 
Net income$1,684 $4,243 
Other comprehensive income (loss)
Change in unrealized gain/loss on derivative instruments, net of tax106 (312)
Other comprehensive income (loss)$106 $(312)
Comprehensive income$1,790 $3,931 
Net income per share
Basic$0.04 $0.11 
Diluted$0.04 $0.11 
Weighted average number of common shares outstanding:
Basic 39,129,407 38,030,854 
Diluted40,663,368 39,677,983 



VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of U.S. Dollars)
(Unaudited)
Three Months Ended March 31,
20212020
Cash flows from operating activities
Net income$1,684 $4,243 
Adjustments for:
Depreciation2,609 2,130 
Change in allowance for doubtful accounts1,819 2,846 
Change in inventory reserve(4)— 
Share-based compensation1,307 1,151 
(Gain) loss on equity method investments(220)27 
Loss (gain) on disposal of property and equipment76 (1,169)
Deferred income taxes (benefit)(222)— 
Net change in working capital
Increase in accounts receivable(2,728)(6,755)
Decrease (increase) in inventory94 (425)
Increase in prepaid expenses and other current assets(161)(2,952)
Increase in trade payables438 3,598 
Increase in deferred revenue13 79 
Decrease in accrued liabilities(77)(2,361)
Increase in income tax payable— 195 
Net cash provided by operating activities$4,628 $607 
Cash flows from investing activities
Purchase of property and equipment(1,797)(4,220)
Investment in equity investments— (32)
Proceeds from sale of property and equipment99 2,541 
Net cash used in investing activities$(1,698)$(1,711)
Cash flows from financing activities
Proceeds from exercise of options65 15 
Principal payments on notes payable(37)(33)
Principal payments on term note(414)(395)
Shares redeemed to pay income tax(1,434)— 
Repayments of lease liabilities(994)(3,429)
Net cash used in financing activities$(2,814)$(3,842)
Net increase (decrease) in cash and cash equivalents116 (4,946)
Cash and cash equivalents at beginning of year30,981 13,355 
Cash and cash equivalents at end of period$31,097 $8,409 
Supplemental disclosures of cash flow information
Cash paid during the period for interest$117 $165 
Cash paid during the period for income taxes, net of refunds received$— $(8)
Supplemental disclosures of non-cash transactions
Property and equipment financed through finance leases$12 $3,002 
Property and equipment financed through operating leases$85 $31 




Non-GAAP Financial Measures

This press release refers to “Adjusted EBITDA” which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, unrealized (gain) loss on warrant conversion liability and stock-based compensation. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:


VIEMED HEALTHCARE, INC.
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA
(Expressed in thousands of U.S. Dollars)
(Unaudited)
For the quarter endedMarch 31, 2021December 31, 2020September 30, 2020June 30, 2020March 31, 2020December 31, 2019September 30, 2019June 30, 2019
Net Income$1,684 $5,071 $2,804 $19,412 $4,243 $2,388 $2,853 $1,326 
Add back:
Depreciation2,609 2,835 2,425 2,190 2,130 2,003 1,659 1,444 
Interest expense91 100 116 135 158 212 56 20 
Unrealized (gain) loss on warrant conversion liability— — — — — — (800)268 
Stock-based compensation1,307 1,301 1,234 1,196 1,151 908 1,064 1,034 
Income tax expense (benefit)(223)151 1,141 (6,646)187 58 51 24 
Adjusted EBITDA$5,468 $9,458 $7,720 $16,287 $7,869 $5,569 $4,883 $4,116 

Use of Non-GAAP Financial Measures

Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. It is not a measurement of the Company’s financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company’s operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company’s industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.





VIEMED HEALTHCARE, INC.
Key Financial and Operational Information
(Expressed in thousands of U.S. Dollars, except vent patients)
(Unaudited)
For the quarter endedMarch 31,
2021
December 31, 2020September 30, 2020June 30, 2020March 31, 2020December 31, 2019September 30, 2019June 30, 2019
Financial Information:
Revenue$28,416 $31,202 $33,447 $42,854 $23,806 $21,448 $20,368 $20,325 
Gross Profit$17,742 $19,178 $19,453 $25,927 $15,553 $14,243 $14,050 $14,639 
Gross Profit %62 %61 %58 %61 %65 %66 %69 %72 %
Net Income$1,684 $5,071 $2,804 $19,412 $4,243 $2,388 $2,853 $1,326 
Cash (As of)$31,097 $30,981 $32,396 $29,707 $8,409 $13,355 $12,630 $7,691 
Total Assets (As of)$113,001 $112,560 $113,969 $112,178 $86,801 $82,596 $79,981 $71,014 
Adjusted EBITDA(1)
$5,468 $9,458 $7,720 $16,287 $7,869 $5,569 $4,883 $4,116 
Operational Information:
Vent Patients(2)
7,733 7,892 7,788 7,705 7,965 7,759 7,421 7,130 
(1)Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.
(2)Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.






EX-101.SCH 3 vmd-20210503.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 vmd-20210503_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 vmd-20210503_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 vmd-20210503_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Ex Transition Period Entity Ex Transition Period Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 7 vmd-20210503_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 vmd-20210503_htm.xml IDEA: XBRL DOCUMENT 0001729149 2021-05-03 2021-05-03 0001729149 false 8-K 2021-05-03 Viemed Healthcare, Inc. Z4 001-38973 625 E. Kaliste Saloom Rd. Lafayette LA 70508 337 504-3802 false false false false Common shares, no par value VMD NASDAQ true false 2021-05-03 2021-05-03 XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover
May 03, 2021
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 03, 2021
Entity Registrant Name Viemed Healthcare, Inc.
Entity File Number 001-38973
Entity Incorporation, State or Country Code Z4
Entity Address, Address Line One 625 E. Kaliste Saloom Rd.
Entity Address, Postal Zip Code 70508
Entity Address, City or Town Lafayette
Entity Address, State or Province LA
City Area Code 337
Local Phone Number 504-3802
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares, no par value
Trading Symbol VMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001729149
Amendment Flag false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $R+HU('04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !,BZ-2-TZ:#.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$E8!R;UI:.G#@8K;.QF;+4UB_]@:R1]^R59FS*V!]C1TL^? M/H%:'84."9]3B)C(8KX;7.>ST''-3D11 &1]0J=R.2;\V#R$Y!2-SW2$J/2' M.B+4G*_ (2FC2,$$+.)"9+(U6NB$BD*ZX(U>\/$S=3/,:, .'7K*4)45,#E- MC.>A:^$&F&"$R>7O IJ%.%?_Q,X=8)?DD.V2ZON^[)LY-^Y0P=O3[F5>M[ ^ MD_(:QU_9"CI'7+/KY-=F\[C?,EGSNBKX?<&;??4@ZI6HF_?)]8??3=@%8P_V M'QM?!64+O^Y"?@%02P,$% @ 3(NC4IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !,BZ-2^+8]%B@$ >$ & 'AL+W=O_0L-5.Y/$MH .X090I)N)A]+0[H[LYU>"%M@S=J25Y(# M_/L>&;#9UAR3WL26[?/RZ)SCUU*&*Z6_FYAS2]9I(LU5*[8V^^AY)HQYRLR% MRKB$.PNE4V9AJ)>>R31G41&4)A[U_4LO94*V1L/BVE2/ABJWB9!\JHG)TY3I MS35/U.JJ%;3V%U[$,K;N@C<:9FS)9]S^F4TUC+Q2)1(IET8H231?7+7&P<=K MVG$!Q1-?!%^9@W/BIC)7ZKL;W$=7+=\1\82'UDDP.+SQ"4\2IP0#A^5[]KI@\3&;.#)^HY*N(;'S5ZK=(Q!NA9D'(7O' 7=KT-HT?"GMB&^.TS0GT: M_!SM 4!)04L*6LBU,0KRUWANK(8Z_8U(MDO)=B'9.2)YH\(2UTW&ZR:( MA_?/'Q"(3@G1.0UBRK50$;F5$8$RU?+@2B[A[;-?/GQHR'BW).NB>K?2"KLA M+WPI7,X!\9FEM5RX#KPF*8_()\X2&X=,\S-R+\,+A/"R)+P\A?!.))P\Y^F\ MODUQ#=\/SMO]0:^-\/1*GMXI/# [I3.EF3.5,S*S4$ZB-)FH7%J]@6-4FT9< M_%L'(>R7A/U3",=1I+DQ9_L3\@C/D<^R%@M7O*1=0E MPNH[*&D'[Z*=*F-90KZ)[&@.<<&>W_7["%C@5Y[HOPMMXD90XU>UDK5>B7^ N_>C"J&5IK&2F'X64\U M/P\A/1QZ>/OEYC*"9<'GQ>)(_7"]1K+*^0/;K %9^7Q%#?E?8[([3J,F5SRHPN@!J'G\>QF M_ ?&5%D[/_2.:P(OI0;'OX?W<4T>>'VN<"D?%HL].@@Z XRL M,GR*^_08C"(JS.(N8G+/\E,/H'4$L#!!0 ( $R+HU*? MH!OPL0( .(, - >&PO9KEMW MDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[< M9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20 MIV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/! M)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FS MX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5 M[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7S MJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41 MP+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS M#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U M(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT, M/O'^8* \^>Q\ETWLJ.?]74_P$4$L# M!!0 ( $R+HU*7BKL

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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.viemed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports vmd-20210503.htm q12021earningsrelease.htm vmd-20210503.xsd vmd-20210503_cal.xml vmd-20210503_def.xml vmd-20210503_lab.xml vmd-20210503_pre.xml http://xbrl.sec.gov/dei/2021 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vmd-20210503.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "vmd-20210503_cal.xml" ] }, "definitionLink": { "local": [ "vmd-20210503_def.xml" ] }, "inline": { "local": [ "vmd-20210503.htm" ] }, "labelLink": { "local": [ "vmd-20210503_lab.xml" ] }, "presentationLink": { "local": [ "vmd-20210503_pre.xml" ] }, "schema": { "local": [ "vmd-20210503.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vmd", "nsuri": "http://www.viemed.com/20210503", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20210503.htm", "contextRef": "id2a73fa95d1d4c6db9929162a3aa43d8_D20210503-20210503", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.viemed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20210503.htm", "contextRef": "id2a73fa95d1d4c6db9929162a3aa43d8_D20210503-20210503", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 17 0001729149-21-000068-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001729149-21-000068-xbrl.zip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